Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in immune regulation, inflammation, and neuronal survival. Dysregulated IL-6 signaling is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). This pathway page examines IL-6 family cytokines, their receptors, downstream signaling cascades, and therapeutic targeting strategies for neurodegenerative diseases.
The IL-6 family includes several cytokines that signal through gp130-containing receptor complexes:
| Cytokine | Primary Sources | Key Functions |
|----------|----------------|---------------|
| IL-6 | Microglia, astrocytes, neurons, T cells | Acute phase response, B cell differentiation |
| IL-11 | Bone marrow stromal cells | Thrombopoiesis, anti-inflammatory |
| LIF (Leukemia Inhibitory Factor) | Astrocytes, neurons | Neuronal survival, stem cell maintenance |
| OSM (Oncostatin M) | Macrophages, microglia | Inflammatory responses, tissue remodeling |
| CNTF (Ciliary Neurotrophic Factor) | Astrocytes | Motor neuron survival, myelin maintenance |
| CT-1 (Cardiotrophin-1) | Cardiomyocytes, neurons | Neurotrophic, cardioprotective |
| IL-27 | Dendritic cells, macrophages | Immunomodulatory |
IL-6 signaling is mediated through two distinct receptor systems:
Classical Signaling:
- IL-6 binds to membrane-bound IL-6Rα (CD126)
- This complex recruits gp130 (CD130) signal-transducing subunit
- Activates downstream JAK-STAT, MAPK, and PI3K/Akt pathways
Trans-Signaling:
- IL-6 binds to soluble IL-6Rα (sIL-6R)
- This complex can bind gp130 on cells lacking membrane IL-6R
- Expanded target cell population including neurons and oligodendrocytes
- Pro-inflammatory and pathologically relevant in neurodegeneration
| Receptor |
Primary Ligands |
Expression |
| gp130 (IL6ST) |
IL-6, IL-11, LIF, OSM, CNTF, CT-1 |
Ubiquitous |
| LIFR |
LIF, OSM, CNTF |
Neurons, astrocytes |
| OSMR |
OSM, IL-31 |
Limited |
flowchart TD
A["IL-6"] --> B{"IL-6R Type"}
B -->|"Classical"| CMembrane IL-6Rα
B -->|"Trans-signaling"| DSoluble IL-6Rα
C --> E["gp130Dimerization"]
D --> E
E --> F["JAK1/JAK2/TYK2"]
F --> G["STAT3 Phosphorylation"]
F --> H["Ras/MAPK Cascade"]
F --> I["PI3K/Akt Pathway"]
G --> J["STAT3 Dimerization"]
J --> K["Nuclear Translocation"]
K --> L["Gene Transcription"]
H --> M["ERK1/2 Activation"]
M --> N["Cell Proliferation<br/>Differentiation"]
I --> O["Akt Activation"]
O --> P["Cell Survival<br/>Anti-apoptotic"]
L --> Q["Acute Phase Proteins<br/>Bcl-2, Bcl-xL<br/>MMPs, Cytokines"]
P --> Q
subgraph Neurodegenerati["Neurodegenerative Context"]
Q --> R["Neuroinflammation<br/>Neuronal Death<br/>Gliosis"]
end
The primary signaling cascade in IL-6 responses:
- JAK Activation: JAK1, JAK2, and TYK2 associated with gp130 cytoplasmic domain
- STAT3 Phosphorylation: JAKs phosphorylate STAT3 on Tyr705
- STAT3 Dimerization: Phosphorylated STAT3 forms hom. Nuclear Transodimers
4location: STAT3 dimers translocate to nucleus
- Gene Transcription: Activates transcription of:
- Acute phase proteins (CRP, serum amyloid A)
- Anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1)
- MMPs and other cytokines
- SOCS3 (negative feedback)
IL-6 also activates the Ras-Raf-MEK-ERK cascade:
- Grb2/SOS recruitment to phosphorylated gp130
- Ras activation → Raf → MEK → ERK1/2
- Controls cell proliferation, differentiation, and survival
Phosphatidylinositol 3-kinase pathway:
- PI3K recruitment to phosphorylated gp130
- Akt/PKB activation
- mTOR, GSK-3β, and FOXO transcription factor regulation
- Anti-apoptotic and pro-survival effects
- Induced by STAT3 as feedback inhibitor
- Binds to JAKs and gp130 to block signaling
- Critical for limiting inflammatory responses
- SHP-1: Dephosphorylates JAKs and STAT3
- PTP1B: Dephosphorylates insulin receptor and JAKs
- Metalloproteinases cleave gp130
- Generates soluble gp130 (sgp130)
- sgp130 can neutralize IL-6 trans-signaling
- Increased IL-6 in hippocampus, cortex, and cerebrospinal fluid
- Correlates with disease severity and neurofibrillary tangle burden
- Microglia and astrocytes are primary cellular sources
- Chronic Neuroinflammation: IL-6 promotes microglial activation
- Amyloid-β Interaction: Aβ enhances IL-6 production
- Tau Pathology: IL-6 promotes tau phosphorylation via STAT3
- Synaptic Dysfunction: Impairs LTP and synaptic plasticity
- Blood-Brain Barrier: Increases BBB permeability
- Acute IL-6 can be neurotrophic
- Promotes neurogenesis in subventricular zone
- May have neuroprotective effects in early disease stages
- Elevated CSF and serum IL-6 in PD patients
- Associated with disease progression
- SNc dopaminergic neurons show increased IL-6R
- Dopaminergic Neuron Vulnerability: IL-6 sensitizes neurons to toxicity
- Microglial Activation: Chronic activation contributes to neurodegeneration
- α-Synuclein Interaction: IL-6 may enhance α-syn aggregation
- Mitochondrial Dysfunction: Impairs complex I activity
- Elevated IL-6 in ALS patients (CSF, serum, spinal cord)
- Correlates with disease progression rate
- Motor neurons express IL-6R and gp130
- Motor Neuron Toxicity: Direct pro-inflammatory effects
- Glial Activation: Astrocyte and microglia-mediated inflammation
- Excitotoxicity: Modulates glutamate receptor expression
- Protein Aggregation: May affect TDP-43 pathology
- Critical for Th17 cell differentiation
- Elevated in MS lesions and CSF
- Associated with disease relapse
- Autoimmunity: Th17-mediated demyelination
- Blood-Brain Barrier: Increases endothelial permeability
- Oligodendrocyte Death: Direct toxicity
- Remyelination Failure: Inhibits oligodendrocyte precursor differentiation
| Drug |
Target |
Status |
Notes |
| Tocilizumab |
IL-6R |
Approved (RA) |
Being investigated in AD, ALS |
| Sarilumab |
IL-6R |
Approved (RA) |
Phase trials in NDs |
| Satralizumab |
IL-6R |
Approved (NMOSD) |
Blood-brain barrier penetration |
| Drug |
Target |
Status |
Notes |
| Tofacitinib |
JAK1/2/3 |
Approved (RA) |
Being studied in AD |
| Baricitinib |
JAK1/2 |
Approved (RA) |
Neuroprotective in models |
| Ruxolitinib |
JAK1/2 |
Approved (MF) |
Reduces neuroinflammation |
- Direct STAT3 inhibitors in development
- Preclinical promise but toxicity concerns
- Curcumin: Modulates IL-6 signaling
- Resveratrol: Reduces IL-6 expression
- Omega-3 fatty acids: Anti-inflammatory effects
- CSF IL-6: Elevated in AD, PD, ALS, MS
- Serum IL-6: Correlates with disease progression
- Longitudinal Tracking: May predict progression rate
- IL-6 levels may predict anti-IL-6 therapy response
- Monitored in clinical trials
- IL-6 vs. IL-6R Targeting: Understanding differential effects
- Trans-signaling Specificity: Developing selective inhibitors
- Cell-Type Specific Effects: Targeting microglia vs. neurons
- Biomarker Development: IL-6 as disease marker
- Combination Therapies: IL-6 inhibition with other approaches